Last reviewed · How we verify
AntiPD1
At a glance
| Generic name | AntiPD1 |
|---|---|
| Sponsor | Azienda Ospedaliera di Perugia |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer. (PHASE1)
- Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma (PHASE2)
- Anti PD-1 Plus Postbiotic Versus Anti PD-1 Alone in Locally Advanced or Metastatic, Treatment naïve, Cutaneous Melanoma Study (NA)
- Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma (PHASE1, PHASE2)
- Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists (NA)
- Triple BRAFinh/MEKinh /antiPD1 Combined Therapy in Patients With BRAF Mutated Melanoma With Central Nervous System Metastasis
- A Study to Evaluate the Combination of Nivolumab With ADG106 in Metastatic NSCLC (PHASE1, PHASE2)
- Bullous Pemphigoid Induced by antiPD-1/PDL-1 Therapy
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AntiPD1 CI brief — competitive landscape report
- AntiPD1 updates RSS · CI watch RSS
- Azienda Ospedaliera di Perugia portfolio CI